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ABSTRACT
Aims/Introduction: To determine the efficacy and safety of ipragliflozin in combination
with metformin in Asian patients with type 2 diabetes mellitus.
Materials and Methods: This phase 3, multicenter, placebo-controlled, double-blind,
parallel-group study was carried out at 18 sites in Korea and 12 sites in Taiwan. After an
8-week washout period for patients using drugs other than metformin and a 2-week run-
in period, patients were randomized to either 50 mg ipragliflozin or a placebo for
24 weeks while continuing metformin. Efficacy outcomes included the changes in hemo-
globin A1c, fasting plasma glucose (FPG) and bodyweight from baseline to the end of
treatment (with last observation carried forward). Safety outcomes included treatment-
emergent adverse events.
Results: Between November 2011 and January 2013, 171 patients were randomized to
and administered ipragliflozin (n = 87) or a placebo (n = 83). The mean changes (stan-
dard deviation) in hemoglobin A1c were -0.94% (0.75%) and -0.47% (0.81%) in the ipra-
gliflozin and placebo groups, respectively (between-group difference -0.46%, P < 0.001).
The changes in fasting plasma glucose and bodyweight were also significantly greater in
the ipragliflozin group, with between-group differences of -14.1 mg/dL and -1.24 kg,
respectively (both P < 0.001). The most common treatment-emergent adverse events
(ipragliflozin vs placebo) were upper respiratory tract infection (9.2% vs 12.0%) and urinary
tract infection (6.9% vs 2.4%).
Conclusions: These results show that ipragliflozin is effective and well tolerated when
used in combination with metformin in Asian patients with type 2 diabetes mellitus.
INTRODUCTION
Recent estimates of the International Diabetes Federation indi-
cate that type 2 diabetes mellitus affects approximately 138 mil-
lion people in the Western Paciﬁc region alone, increasing to
202 million people by 20351. Furthermore, approximately one-
third of all patients with type 2 diabetes mellitus are in the Wes-
tern Paciﬁc region. The rising incidence of type 2 diabetes melli-
tus is accompanied by increasing trends towards obesity and
overweight2, which are especially apparent in Asian countries.Received 15 April 2015; revised 6 August 2015; accepted 25 August 2015
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CLINICAL TRIAL
The pathophysiology of type 2 diabetes mellitus differs
slightly between Asian patients and other patient populations in
terms of greater insulin resistance, and reduced insulin secretion
in Asian patients2,3. Additionally, Asian patients tend to develop
diabetes at a lower body mass index relative to Western popu-
lations2.
Current treatment recommendations for type 2 diabetes mel-
litus highlight the importance of diet and exercise as initial
therapy, followed by the addition of a glucose-lowering drug,
commonly metformin4,5. Other available drug classes for initial
or second-line therapy, including sulfonylureas and incretin
modulators, improve glycemic control by enhancing insulin
secretion. However, increased insulin resistance and a reduced
insulin secretion capacity might limit the efﬁcacy of these
drugs. Therefore, other classes of drugs that lower blood glu-
cose in an insulin-independent manner are required.
Sodium-glucose cotransporter 2 (SGLT2) is a glucose trans-
porter that is primarily expressed in proximal tubules, where it
is responsible for approximately 90% of the glucose reabsorp-
tion in the kidney6. Some studies have suggested that SGLT2
expression is increased in diabetic rats7 and in human exfoli-
ated proximal tubular epithelial cells obtained from urine sam-
ples of patients with type 2 diabetes mellitus8. Several SGLT2
inhibitors are currently under development or have been
approved in some countries for the treatment of type 2
diabetes mellitus; these lower blood glucose levels by preventing
glucose reabsorption in the kidney in an insulin-independent
manner9–11.
Ipragliﬂozin, a SGLT2 inhibitor, was ﬁrst approved in Japan
for the treatment of type 2 diabetes mellitus based on the
results of clinical trials in Japanese patients with type 2 diabetes
mellitus when used as both monotherapy12,13 and in dual com-
bination with other glucose-lowering agents, including met-
formin14. Because SGLT2 inhibitors improve glycemic control
in an insulin-independent manner, they are expected to be use-
ful in Asian patients with type 2 diabetes mellitus, especially
considering the reduced insulin secretory capacity in Asians2,3.
Until now, no studies have focused on ipragliﬂozin in non-
Japanese Asian patients. Therefore, the present study aimed to
examine the efﬁcacy and safety of ipragliﬂozin in combination
with metformin in Taiwanese and Korean patients with type 2
diabetes mellitus.
MATERIALS AND METHODS
Patients
Korean or Taiwanese patients who met the following criteria
were eligible for the present study: age ≥20 years, diagnosis of
type 2 diabetes mellitus ≥12 weeks before enrolment, stable diet
and exercise regimen for ≥8 weeks, hemoglobin A1c (HbA1c)
between 7.0 and 10.0%, and body mass index between 20.0 and
45.0 kg/m2. Patients using metformin were also eligible pro-
vided metformin was administered at a stable dose of
≥1,500 mg/day (or ≥1,000 mg/day if safety concerns prohib-
ited higher doses) for ≥8 weeks. The exclusion criteria are
summarized in the Supporting Information. All patients pro-
vided written informed consent.
Study design and treatments
The present phase 3, multicenter, placebo-controlled, double-
blind, parallel-group study was carried out at 18 sites in Korea
and 12 sites in Taiwan. The study consisted of a single-blind,
2-week placebo run-in period (visit 1), a 24-week double-blind
treatment period (visits 2–9) and a 4-week follow-up period
(visits 9–10). Visits 2–9 were scheduled at weeks 0, 2, 4 and
every 4 weeks thereafter; visit 9 (week 24) was deﬁned as the
end of treatment. An additional visit was scheduled for patients
who withdrew before visit 9. Patients using hypoglycemic drugs
other than metformin entered an 8-week washout period before
visit 1.
Patients who met the eligibility criteria at visit 1 were ran-
domized at visit 2 to receive 50 mg ipragliﬂozin or a placebo
in a 1:1 ratio with stratiﬁcation for study site and HbA1c at
visit 1 (<8.0% or ≥8.0%) using an interactive web randomiza-
tion system with treatment codes prepared by an independent
assignment manager. The study drugs were identical in size,
color and appearance, and were provided in identical packag-
ing. To maintain blinding, the patients and investigators were
blinded to the treatment codes. The treatment code was broken
once the study database was locked.
During the study, patients were prohibited from using anti-
diabetic drugs other than the study drug and metformin, pro-
vided metformin was continued at the same dose. Patients
were also prohibited from continuous systemic administration
of corticosteroids, immunosuppressants or loop diuretics for
chronic diseases; however, these drugs were allowed for topical
or temporary use. Changes to diet and exercise therapy were
also prohibited.
Treatment compliance was assessed in terms of the number
of prescribed and returned tablets, the number of tablets lost,
and patient diaries at each visit.
The study protocol, case report forms and patient informa-
tion sheets were approved by institutional review boards at each
participating site. The study was carried out in accordance with
Good Clinical Practice, International Conference on Harmo-
nization Technical Requirements for Registration of Pharma-
ceuticals for Human Use, as well as applicable local laws and
regulations.
Efﬁcacy and safety outcomes
The primary efﬁcacy outcome was HbA1c (National Glycohe-
moglobin Standardization Program units), which was mea-
sured every 4 weeks. Secondary efﬁcacy outcomes included
proportions of patients with HbA1c <7.0% or <6.5% at each
visit, fasting plasma glucose (FPG; measured at each visit),
bodyweight (measured at each visit), waist circumference (vis-
its 2 and 9), and fasting serum insulin (FSI; visits 2, 6 and 9).
For all efﬁcacy outcomes, the value measured at visit 2 was
used as the baseline value.
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The main safety outcomes were adverse events (AEs), vital
signs, hematology, serum chemistry and urinalysis, which
were assessed at visits 2–10. Other safety outcomes included
urinalysis for bacteria and sediment (visits 2, 5, 7 and 9),
bone turnover markers (visits 2, 6, 9 and 10) and bone meta-
bolism markers (visits 2, 9 and 10). All protocol-deﬁned clini-
cal laboratory assessments were carried out at a central
laboratory (Mitsubishi Chemical Medience Corporation,
Tokyo, Japan) using routine methods. AEs were reported in
terms of system organ class and preferred term using the
MedDRA version 14.0, and classiﬁed in terms of severity,
seriousness and causal relationship to the study drug. AEs
that occurred after the ﬁrst dose of the study drug in the
treatment period were deﬁned as treatment-emergent adverse
events (TEAEs). Serious AEs were any untoward medical
events that resulted in death, were life-threatening, resulted in
persistent or signiﬁcant disability/incapacity, resulted in a con-
genital anomaly or birth defect, required inpatient hospitaliza-
tion or prolonged hospitalization and other medically
important events. AEs were also graded as mild (no disrup-
tion of normal daily activities), moderate (affected normal
daily activities) or severe (inability to carry out daily activi-
ties). To maintain blinding, investigators and patients were
not to carry out urinary glucose tests, unless deemed essential
for safety reasons.
Statistical analysis
A total of 40 patients per country were planned for enrolment
to satisfy local regulations and the recommendation of the
respective health authorities. From a statistical viewpoint, enrol-
ment of at least 80 participants per group provided over 90%
power to show the statistical difference with a two-sided signiﬁ-
cance level of 0.05, based on the results of a Japanese dose-
ﬁnding study12.
Primary and secondary efﬁcacy variables were evaluated in
the full analysis set, comprising all patients who received at
least one dose of the study drug in the treatment period, and
in whom the efﬁcacy variable was measured at least once after
starting administration of the study drug. Safety variables were
assessed in the safety analysis set, which consisted of all patients
who received at least one dose of the study drug during the
treatment period.
For efﬁcacy and safety variables, missing values were
imputed using the last observation carried forward method.
Statistical analyses were carried out by combining data for
both countries and for each country individually. Baseline
characteristics are summarized as the mean (standard devia-
tion) for continuous variables, or the n (%) for categorical
variables. Two-sample t-tests and Fisher’s exact test were used
to compare continuous and categorical variables, respectively,
between the groups.
The change in HbA1c from baseline to the end of treatment
(with last observation carried forward) was compared between
the groups using analysis of covariance (ANCOVA) with the
baseline value as a covariate, and treatment group and country
as ﬁxed effects. The mean difference between the ipragliﬂozin
and placebo groups (between-group difference) was also calcu-
lated using the ANCOVA model. Sensitivity analyses were carried
out using the per-protocol set, by ANCOVA with interactions
among the included variables, and by ANCOVA for each country
individually. The changes in FPG, FSI, bodyweight and waist
circumference were assessed as described for the change in
HbA1c. AEs are summarized descriptively as the n (%) of
patients in each group.
RESULTS
Patient disposition and characteristics
Between November 2011 and January 2013, 238 patients pro-
vided informed consent. Of 171 who were randomized at visit
2, 87 received ipragliﬂozin and 83 received a placebo in the
treatment period (Figure S1). These patients were included in
the full analysis set and safety analysis set. One patient assigned
to the placebo group discontinued before administration of the
study drug and was not included in the full analysis set or
safety analysis set. Overall, 74 and 69 patients treated with ipra-
gliﬂozin and placebo, respectively, completed the study. As
shown in Table S1, the characteristics of both groups were
comparable, except for a slight imbalance in the proportion of
patients with an estimated glomerular ﬁltration rate of
<90 mL/min/1.73 m2. The mean (standard deviation) duration
of exposure to the study drug was 155 (39) and 149 (47) days
in the ipragliﬂozin and placebo groups, respectively. Treatment
compliance was high, with mean compliance rates of 97% in
both groups.
Efﬁcacy
Glycemic Control
As shown in Figure 1a, HbA1c decreased signiﬁcantly over time
to a greater extent in the ipragliﬂozin group than in the placebo
group. The mean (standard deviation) change from baseline to
the end of treatment was -0.94% (0.75%) and -0.47% (0.81%)
in the ipragliﬂozin and placebo groups, respectively, with a
between-group difference of -0.46% (95% conﬁdence interval
[CI] -0.66 to -0.27%; P < 0.001). Similar differences were also
observed in subgroup analyses after stratifying patients by sex,
age and baseline HbA1c (data not shown). The proportion of
patients with HbA1c <7.0% increased from 11.5% (10/87) at
baseline to 69.4% (59/85) at the end of treatment in the ipragli-
ﬂozin group, and from 3.6% (3/83) to 44.6% (37/83) in the pla-
cebo group. The proportion of patients with HbA1c <6.5%
increased from 1.1% (1/87) at baseline to 25.9% (22/85) at the
end of treatment in the ipragliﬂozin group, and from 0% (0/83)
to 9.6% (8/83) in the placebo group.
Figure 1b shows the time-course of FPG levels in both
groups. FPG decreased over time in both groups, and remained
lower in the ipragliﬂozin group than in the placebo group
from week 2 until the end of treatment. The mean change in
FPG from baseline to the end of treatment was signiﬁcantly
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greater in the ipragliﬂozin group than in the placebo group
(24.1 vs -5.7 mg/dL; between-group difference -14.1 mg/dL
[95% CI -21.1 to -7.2 mg/dL; P < 0.001]).
Other Secondary Efﬁcacy and Laboratory Outcomes
Bodyweight decreased over time in both groups (Figure S2a),
but the mean change from baseline to the end of treatment
was signiﬁcantly greater in the ipragliﬂozin group than in the
placebo group (-2.93 vs -1.70 kg), with a between-group dif-
ference of -1.24 kg (95% CI -1.92 to -0.56 kg; P < 0.001). By
the end of treatment, 33.3% (29/87) and 18.1% (15/83) of
patients in the ipragliﬂozin and placebo groups, respectively,
had a weight reduction of ≥5%.
Consistent with the change in bodyweight, the reduction in
waist circumference (Figure S2b) was signiﬁcantly greater in the
ipragliﬂozin group (-1.72 vs -0.85 cm; between-group differ-
ence -0.91 cm; 95% CI -1.74 to -0.08 cm; P = 0.032).
Although FSI decreased in the ipragliﬂozin group and increased
in the placebo group (change in FSI with ipragliﬂozin vs pla-
cebo -0.99 [9.91] vs 0.22 [6.34] lU/mL; P = 0.321), the differ-
ence was not signiﬁcant. The changes in homeostasis model
assessment of insulin resistance (-0.78 [3.373] vs -0.05 [2.793];
P = 0.111) were similar between the ipragliﬂozin and placebo
groups. Plasma triglyceride levels decreased signiﬁcantly in the
ipragliﬂozin group, but increased in the placebo group (-24.6
[91.9] vs 10.7 [79.6] mg/dL; P = 0.008). The increase in
high-density lipoprotein cholesterol was slightly greater in the
ipragliﬂozin group, while the increase in total cholesterol and
decrease in low-density lipoprotein (LDL) cholesterol were
slightly greater in the placebo group than in the ipragliﬂozin
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Figure 1 | Time-courses of (a) hemoglobin A1c (HbA1c) and (b) fasting plasma glucose (FPG) measurements. Values are mean (standard deviation
[SD]). CI, confidence interval; NGSP, National Glycohemoglobin Standardization Program.
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group (Table 1). The change in free fatty acids was similar in
both groups. The decrease in estimated glomerular ﬁltration
rate at the end of treatment was greater in the placebo group
(-18.28 [49.27] mL/min/1.73 m2] than in the ipragliﬂozin
group (-9.86 [40.29] mL/min/1.73 m2), although the difference
between groups did not reach statistical signiﬁcance.
Systolic and diastolic blood pressures decreased to a greater
extent in the ipragliﬂozin group (systolic/diastolic blood pres-
sure -6.8 [14.1]/-3.7 [9.4] mmHg) than in the placebo group
(-1.3 [12.9]/-1.0 [8.0] mmHg; Table 1).
Safety
TEAEs occurred in just over one-half of the patients, and drug-
related TEAEs occurred in approximately one-ﬁfth of the
patients in each group (Table 2). All of the TEAEs and drug-
related TEAEs were classiﬁed as mild or moderate in severity.
Two patients in the ipragliﬂozin group and one in the placebo
group discontinued treatment because of TEAEs. Meanwhile,
serious TEAEs occurred in 2.3% (2/87) and 6.0% (5/83) of
patients in the ipragliﬂozin and placebo groups, respectively.
For one patient in the placebo group, the serious TEAEs were
considered to be study drug-related. The serious TEAEs in the
ipragliﬂozin group were synovial cyst and knee arthroplasty in
one patient each, while those in the placebo group were con-
cussion, spinal disorder and contusion in one patient;
hydronephrosis, ureteric stenosis and acute pyelonephritis in
one patient (all considered study drug-related); and compres-
sion fracture, colonic polyp and increased alanine aminotrans-
ferase in one patient each.
The most common TEAEs in the ipragliﬂozin group were
upper respiratory tract infection (9.2%; 8/87) and urinary tract
infection (6.9%; 6/87). Other TEAEs occurred in <4 patients in
the ipragliﬂozin group. Upper respiratory tract infection and uri-
nary tract infection occurred in 12.0% (10/83) and 2.4% (2/83)
of patients, respectively, in the placebo group. The most com-
mon drug-related TEAEs in the ipragliﬂozin group were uri-
nary tract infection (6.9%; 6/87) and decreased weight (3.4%; 3/
87). The corresponding rates of these TEAEs in the placebo
group were 2.4% (2/83) and 1.2% (1/83). There were no epi-
sodes of hypoglycemia or genital infection in either group.
Polyuria occurred in one patient (1.1%) in the ipragliﬂozin
group, and pollakiuria occurred in four patients (4.8%) in the
placebo group.
Table 3 summarizes the changes in variables related to
hematology, renal function, liver function and electrolytes.
There were no apparent differences in these laboratory vari-
ables, with the exception of slightly greater increases in the red
blood cell count, hemoglobin, hematocrit, urine osmolality,
blood urea nitrogen, blood urea nitrogen/creatinine ratio, mag-
nesium, urine potassium:creatinine ratio and urine phosphorus:
creatinine ratio in the ipragliﬂozin group than in the placebo
group. There were no apparent differences in bone markers,
liver function markers or other laboratory variables.
DISCUSSION
The present phase 3 study was carried out to examine the efﬁ-
cacy and safety of ipragliﬂozin in combination with metformin
in Asian patients with type 2 diabetes mellitus inadequately
controlled with metformin. In this study, ipragliﬂozin signiﬁ-
cantly improved glycemic control in terms of both HbA1c and
FPG, and led to reductions in bodyweight and waist circumfer-
ence, and improvements in other clinical/laboratory variables
compared with the placebo. Ipragliﬂozin was well tolerated
without being associated with any previously undocumented
TEAEs, and its safety proﬁle was comparable with that of the
placebo, with only urinary tract infection being slightly more
common in the ipragliﬂozin group than in the placebo group.
Many existing treatment options for type 2 diabetes mellitus
are ultimately reliant on insulin. Therefore, they might have
limited glucose-lowering effects in some Asian patients, espe-
cially those with increased insulin resistance and/or insulin
secretory defects, highlighting the need for alternative classes of
drugs that lower glucose in an insulin-independent manner.
SGLT2 inhibitors, such as ipragliﬂozin, lower plasma glucose
Table 1 | Clinical and laboratory parameters (safety analysis set)
Variable Change† in the placebo group (n = 83) Change† in the ipragliflozin group (n = 87) P-value¶
Triglycerides (mg/dL) 10.7 (79.6) -24.6 (91.9) 0.008§
FFA (mEq/L) -0.084 (0.322) -0.020 (0.304) 0.183
Total cholesterol (mg/dL) 5.3 (27.2) 2.1 (27.5) 0.445
HDL cholesterol (mg/dL) 0.9 (7.0) 2.6 (7.0) 0.118
LDL cholesterol (mg/dL) -2.0 (27.2) -0.8 (29.9) 0.798
eGFR (mL/min/1.73 m2) -18.28 (49.27) -9.86 (40.29) 0.224
SBP (mmHg) -1.3 (12.9) -6.8 (14.1) 0.009§
DBP (mmHg) -1.0 (8.0) -3.7 (9.4) 0.047‡
Pulse rate (/min) -1.9 (9.9) -2.1 (8.7) 0.889
Values are means (standard deviation). †Change from baseline to the end of treatment. ‡P < 0.05 versus placebo; §P < 0.01 versus placebo; ¶t-test.
DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FFA, free fatty acids; HDL, high-density lipoprotein; LDL, low-density lipopro-
tein; SBP, systolic blood pressure.
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levels by reducing renal glucose reuptake, thus enhancing uri-
nary glucose excretion.
The present results compare favorably with those of earlier
studies in Asian patients in which ipragliﬂozin achieved signiﬁ-
cant reductions in HbA1c and FPG when used as monother-
apy13. The results are also consistent with those for
dapagliﬂozin in Asian patients15,16, conﬁrming the glucose-
lowering effects of SGLT2 inhibitors in Asian patients. The pre-
sent study was carried out in a similar manner to the ILLUMI-
NATE study in Japanese patients treated with metformin14. In
the ILLUMINATE study, the mean changes in HbA1c in
the ipragliﬂozin and placebo groups were -0.87% and 0.38%,
respectively, corresponding to a between-group difference of
-1.30% (95% CI -1.501 to -1.095%; P < 0.001). In the present
study, the mean change in HbA1c in the ipragliﬂozin group
was -0.94%, compared with -0.47% in the placebo group,
resulting in a between-group difference of -0.46% (95% CI
-0.66 to -0.27%; P < 0.001). Although the reason for the larger
reduction in HbA1c in the placebo group in the present study
is unclear, the further reduction in HbA1c in the ipragliﬂozin
group is clinically important, and ensured that greater propor-
tions of patients achieved a HbA1c of <7.0% or <6.5% at the
end of treatment.
In the present study, we also observed small but favorable
changes in bodyweight, waist circumference, blood pressure
and triglycerides in the ipragliﬂozin group compared with the
placebo group, whereas the changes in LDL cholesterol and
total cholesterol were smaller in the ipragliﬂozin group than in
the placebo group. Similar beneﬁcial changes in blood pressure
and triglycerides were also observed in the ILLUMINATE
study14, which suggest that the glucose-lowering effects of ipra-
gliﬂozin are associated with beneﬁcial changes in other clinically
relevant parameters. Of note, the reduction in blood pressure
seems to represent a class-effect of SGLT2 inhibitors17.
There were slight increases in the red blood cell count and
hematocrit in the ipragliﬂozin group in the present study, as in
the ILLUMINATE study14. These changes were probably as a
result of an increase in urine output or water loss, although this
could not be assessed in this study because urine volume was
not measured. However, these changes were not clinically sig-
niﬁcant in this study. We also observed slight increases in uri-
nary potassium and phosphorus levels in the ipragliﬂozin
group, although the cause and clinical relevance of these
changes remain unknown. Intriguingly, there were no episodes
of hypoglycemia, pollakiuria or genital infection, while the rates
of nasopharyngitis, polyuria and urinary tract infection were
quite low. Of these, only urinary tract infection occurred in
more patients in the ipragliﬂozin group than in the placebo
group. Skin disorders have also been reported in some Japanese
patients using SGLT2 inhibitors, prompting the Japanese Dia-
betes Society to issue recommendations regarding the use of
SGLT2 inhibitors18. In the present study, skin and subcuta-
neous tissue disorders included alopecia, which occurred in 0.0
and 2.3% of patients in the placebo and ipragliﬂozin groups,
respectively, and pruritis, which occurred in 2.4 and 2.3% of
patients, respectively.
The present results also warrant comparison with the results
of an 18-week study in which Asian patients on metformin
alone or metformin plus sulfonylurea were randomized to
100 mg canagliﬂozin, 300 mg canagliﬂozin or a placebo19. The
changes in HbA1c from baseline to the end of treatment were
-0.97, -1.06 and -0.47% for 100 mg canagliﬂozin, 300 mg
canagliﬂozin and the placebo, respectively, corresponding to
placebo-subtracted changes of -0.51 and -0.59% for 100 mg
and 300 mg canagliﬂozin, respectively. The placebo-subtracted
changes in bodyweight were -1.5 and -1.6 kg for 100 and
300 mg canagliﬂozin, respectively. The reduction in bodyweight
was slightly greater during the ﬁrst 3 weeks of the study than
from week 3 to week 18. These changes in HbA1c and body-
weight were similar to those observed in the present study. The
authors also observed reductions in blood pressure and trigly-
cerides, and increases in high-density lipoprotein cholesterol
and LDL cholesterol. Such increases in LDL cholesterol were
Table 2 | Treatment-emergent adverse events (safety analysis set)
Placebo Ipragliflozin
n 83 87
All TEAEs 51 (61.4) 50 (57.5)
No. TEAEs 131 130
TEAEs by severity
Mild 41 (49.4) 40 (46.0)
Moderate 10 (12.0) 10 (11.5)
Severe 0 (0) 0 (0)
Serious TEAEs 5 (6.0) 2 (2.3)
TEAEs leading to study discontinuation 1 (1.2) 2 (2.3)
Drug-related TEAEs 17 (20.5) 17 (19.5)
No. drug-related TEAEs 34 29
Drug-related TEAEs by severity
Mild 13 (15.7) 15 (17.2)
Moderate 4 (4.8) 2 (2.3)
Severe 0 (0) 0 (0)
Serious drug-related TEAEs 1 (1.2) 0 (0)
Drug-related TEAEs leading to
study discontinuation
1 (1.2) 2 (2.3)
TEAEs in ≥ 3% of patients in
either group
Upper respiratory tract infection 10 (12.0) 8 (9.2)
Urinary tract infection 2 (2.4) 6 (6.9)
Proteinuria 3 (3.6) 3 (3.4)
Nasopharyngitis 3 (3.6) 2 (2.3)
Dysuria 3 (3.6) 2 (2.3)
Dizziness 2 (2.4) 3 (3.4)
Weight decreased 1 (1.2) 3 (3.4)
Osteoarthritis 3 (3.6) 1 (1.1)
Bilirubin conjugated increased 3 (3.6) 0 (0)
Nocturia 3 (3.6) 0 (0)
Constipation 0 (0) 3 (3.4)
Values are n (%) of patients. TEAEs, treatment-emergent adverse events.
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not observed in the present study. Urinary tract infections
occurred in 3.1, 2.6 and 4.9% of patients in the 100 mg canagli-
ﬂozin, 300 mg canagliﬂozin and placebo groups, respectively,
while osmotic diuresis-related AEs occurred in 0.9, 0.9 and
1.3% of patients, respectively.
Some limitations of the present study warrant men-
tion, including the treatment duration of 24 weeks, which
might be too short to examine the longer-term effects on
glycemic control. Another possible limitation was that
approximately two-thirds of patients had HbA1c levels of
<8.0% at baseline, which possibly limited the extent of the
reductions in glucose levels. Finally, the study was carried
out in two Asian countries (Taiwan and Korea). Therefore,
the results might not be generalizable to patients in other
Asian countries or Asian patients living in Western countries.
Nevertheless, the overall results of the present study are
broadly consistent with those of the ILLUMINATE study14,
and support the use of ipragliﬂozin in combination with
metformin for treating Asian patients with type 2 diabetes
mellitus.
In conclusion, the results of this study of Taiwanese and
Korean patients support those of an earlier study of Japanese
patients14, and conﬁrm the efﬁcacy and safety of ipragliﬂozin in
Asian patients with type 2 diabetes mellitus and inadequate gly-
cemic control with metformin alone.
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Table 3 | Hematology and other laboratory variables (safety analysis set)
Variable Change† in the placebo group (n = 83) Change† in the ipragliflozin group (n = 87) P-value††
BUN (mg/dL) 0.7 (3.7) 2.9 (4.2) <0.001¶
Cre (mg/dL) 0.050 (0.100) 0.031 (0.114) 0.251
BUN:Cre ratio -1.57 (12.00) 3.81 (9.54) 0.001¶
RBC count (9104/lL) -8.7 (20.9) 14.9 (19.5) <0.001¶
Hemoglobin (g/dL) -0.24 (0.77) 0.37 (0.61) <0.001¶
Hematocrit (%) -0.60 (2.01) 1.45 (1.84) <0.001¶
Na (mEq/L) 0.0 (1.9) 0.0 (2.2) 0.940
K (mEq/L) 0.05 (0.34) 0.07 (0.32) 0.663
Cl (mEq/L) -0.2 (2.7) 0.3 (3.3) 0.284
Ca (mg/dL) -0.10 (0.41) -0.09 (0.52) 0.860
Mg (mg/dL) 0.03 (0.14) 0.14 (0.19) <0.001¶
P (mg/dL) -0.01 (0.48) 0.12 (0.51) 0.094
Urine NAG:Cre ratio (U/g Cre) 0.32 (4.78) 0.85 (5.96) 0.526
Urine albumin:Cre ratio (mg/g Cre) 33.08 (282.92) 4.90 (153.16) 0.418
Urine osmolality (mOsm/L) -13.0 (255.2) 72.6 (255.2) 0.030‡
Urine Na/Cre ratio (mEq/g Cre) 16.0 (105.0) 26.5 (94.4) 0.491
Urine K/Cre ratio (mEq/g Cre) 4.55 (35.28) 21.09 (38.42) 0.004§
Urine Cl/Cre ratio (mEq/g Cre) 3.0 (110.6) 21.9 (106.0) 0.256
Urine Ca/Cre ratio (mg/g Cre) 8.98 (88.14) 25.74 (95.74) 0.237
Urine Mg/Cre ratio (mEq/g Cre) 5.12 (35.42) 10.94 (33.26) 0.271
Urine P/Cre ratio (mEq/g Cre) 59.82 (247.54) 197.82 (293.39) 0.001¶
AST (U/L) -3.1 (9.1) -4.8 (8.2) 0.224
ALT (U/L) -8.9 (44.1) -9.3 (17.8) 0.929
Total bilirubin (mg/dL) 0.00 (0.21) 0.03 (0.19) 0.368
Direct bilirubin (mg/dL) 0.00 (0.10) 0.00 (0.09) 0.821
LDH (U/L) -1.3 (25.5) -8.0 (34.2) 0.154
ALP (U/L) -9.7 (60.4) -7.4 (36.5) 0.765
c-GTP (U/L) -7.9 (53.6) -4.7 (29.1) 0.630
CTx (pmol/L) 0.457 (1.130) (n = 81) 0.823 (1.413) (n = 83) 0.069
BAP (lg/L) -0.58 (2.64) (n = 81) -0.61 (2.60) (n = 83) 0.940
Intact PTH (pg/mL) 5.6 (12.1) (n = 79) 6.2 (13.3) (n = 81) 0.779
Urine NTx 2.68 (916.43) (n = 81) 3.61 (21.00) (n = 83) 0.753
Values are means (SD). †Change from baseline to the end of treatment. ‡P < 0.05 versus placebo; §P < 0.01 versus placebo; ¶P ≤ 0.001 versus pla-
cebo; ††t-test. ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate transaminase; BAP, bone-specific alkaline phosphatase; BUN,
blood urea nitrogen; Cre, creatinine; CTx, cross-linked C-terminal telopeptide of type I collagen; c-GTP, c-glutamyl transpeptidase; LDH, lactate dehy-
drogenase; NAG, b-N-acetyl-D-glucosaminidase; NTx, cross-linked N-terminal telopeptide of type I collagen; PTH, parathyroid hormone; RBC, red
blood cells.
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SUPPORTING INFORMATION
Additional Supporting Information may be found in the online version of this article:
Figure S1 | Patient disposition. *This patient did not undergo administration of placebo after randomization, and was excluded
from the full analysis and safety analysis sets.
Figure S2 | Time-courses of the changes in (a) bodyweight and (b) waist circumference measurements. Values are mean (standard
deviation).
Table S1 | Patient characteristics at visit 1 (full analysis set).
Data S1 | Exclusion criteria.
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